MH-76, a Novel Non-Quinazoline α
adipocytokines
adipose tissue
fructose-fed rats
inflammation
insulin resistance
metabolic syndrome
obesity
α1-adrenoceptors antagonist
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
29
03
2021
revised:
09
05
2021
accepted:
12
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Quinazoline α Abdominal adipose tissue was collected from four groups of fructose-fed rats (Control, Fructose, Fructose + MH-76 and Fructose + Prazosin) and subjected to biochemical, histopathological and immunohistochemical studies. Moreover, selected tissue distribution studies were performed. Treatment with MH-76 but not with prazosin improved endothelial integrity, reduced adipose tissue inflammation and infiltration by immune cells, resulting in lowering leptin, MCP-1, IL-6, TNF-α and PAI-1 levels. In adipose tissue from Fructose + MH-76 animals, a higher amount of eosinophils accompanied with higher IL-4 concentration was observed. Treatment with MH-76 but not with prazosin markedly reduced phosphorylation of IRS-1 at Ser307. MH-76 may improve insulin signaling in adipose tissue by reducing the pro-inflammatory cytokine production and inhibiting the inflammatory cells recruitment. In contrast, in adipose tissue from animals treated with prazosin, the inflammatory effect was clearly enhanced.
Sections du résumé
BACKGROUND
BACKGROUND
Quinazoline α
METHODS
METHODS
Abdominal adipose tissue was collected from four groups of fructose-fed rats (Control, Fructose, Fructose + MH-76 and Fructose + Prazosin) and subjected to biochemical, histopathological and immunohistochemical studies. Moreover, selected tissue distribution studies were performed.
RESULTS
RESULTS
Treatment with MH-76 but not with prazosin improved endothelial integrity, reduced adipose tissue inflammation and infiltration by immune cells, resulting in lowering leptin, MCP-1, IL-6, TNF-α and PAI-1 levels. In adipose tissue from Fructose + MH-76 animals, a higher amount of eosinophils accompanied with higher IL-4 concentration was observed. Treatment with MH-76 but not with prazosin markedly reduced phosphorylation of IRS-1 at Ser307.
CONCLUSION
CONCLUSIONS
MH-76 may improve insulin signaling in adipose tissue by reducing the pro-inflammatory cytokine production and inhibiting the inflammatory cells recruitment. In contrast, in adipose tissue from animals treated with prazosin, the inflammatory effect was clearly enhanced.
Identifiants
pubmed: 34069933
pii: ph14050477
doi: 10.3390/ph14050477
pmc: PMC8157569
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Centre
ID : DEC-2014/15/D/NZ7/01807
Références
Biomed Res Int. 2017;2017:2494067
pubmed: 28497040
Endocr Metab Immune Disord Drug Targets. 2019;19(4):481-489
pubmed: 30499422
Nutr Metab Cardiovasc Dis. 2019 Jul;29(7):751-760
pubmed: 31133498
Biomed Pharmacother. 2017 Sep;93:352-358
pubmed: 28651236
Clin Biochem. 2009 Sep;42(13-14):1331-46
pubmed: 19501581
Nutrients. 2017 Mar 29;9(4):
pubmed: 28353649
Biochimie. 2005 Jan;87(1):99-109
pubmed: 15733744
Nutrients. 2017 Apr 26;9(5):
pubmed: 28445389
J Clin Invest. 2008 Feb;118(2):710-21
pubmed: 18202748
Hypertens Res. 2019 Aug;42(8):1125-1141
pubmed: 30872813
Front Endocrinol (Lausanne). 2019 Oct 30;10:703
pubmed: 31736870
Curr Hypertens Rep. 2016 Jun;18(6):44
pubmed: 27125390
Sci Rep. 2018 Jul 2;8(1):9894
pubmed: 29967467
Metabolism. 2017 Jul;72:120-143
pubmed: 28641779
Front Pharmacol. 2016 Dec 20;7:495
pubmed: 28066244
Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):137-47
pubmed: 16487914
World J Gastroenterol. 2014 Feb 21;20(7):1807-21
pubmed: 24587658
J Leukoc Biol. 2020 Jul;108(1):123-128
pubmed: 32170879
Naunyn Schmiedebergs Arch Pharmacol. 2009 Dec;380(6):473-7
pubmed: 19904527
Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):1479-1490
pubmed: 32268785
J Diabetes Complications. 2019 Aug;33(8):535-538
pubmed: 31204245
J Hypertens. 2010 Sep;28(9):1796-803
pubmed: 20543713
Biomed Res Int. 2014;2014:263897
pubmed: 25045660
Eur J Pharmacol. 2013 Jan 5;698(1-3):335-44
pubmed: 23117089
J Pharmacol Sci. 2013;122(2):93-102
pubmed: 23698110
Exp Cell Res. 2011 Oct 1;317(16):2239-51
pubmed: 21781962
Cell Immunol. 2017 May;315:18-26
pubmed: 28285710
Food Funct. 2016 Mar;7(3):1544-53
pubmed: 26901521
Can J Physiol Pharmacol. 2013 Nov;91(11):867-72
pubmed: 24117253
Front Pharmacol. 2018 Sep 26;9:1087
pubmed: 30319420
Circulation. 2003 Jan 7;107(1):127-31
pubmed: 12515754
Am Heart J. 2006 Nov;152(5):842-50
pubmed: 17070143
Physiol Rev. 2010 Jan;90(1):23-46
pubmed: 20086073
J Cell Commun Signal. 2014 Mar;8(1):13-22
pubmed: 24026800
Biomed Pharmacother. 2018 Jul;103:157-166
pubmed: 29653360
Science. 2011 Apr 8;332(6026):243-7
pubmed: 21436399
Crit Rev Clin Lab Sci. 2015;52(6):301-13
pubmed: 26292076
IUBMB Life. 2009 Apr;61(4):424-30
pubmed: 19319966
Diabetes Metab Syndr. 2019 Jul - Aug;13(4):2409-2417
pubmed: 31405652
Arch Immunol Ther Exp (Warsz). 2013 Apr;61(2):119-25
pubmed: 23307037
Cardiovasc Res. 2006 Jul 1;71(1):118-28
pubmed: 16631627
Pharmazie. 2011 Oct;66(10):733-9
pubmed: 22026152
Biomed Pharmacother. 2020 Nov;131:110795
pubmed: 33152951